References
- Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS 2015; 10:129-34; PMID:25760933; https://doi.org/http://dx.doi.org/10.1097/COH.0000000000000154
- Pollack P, Groothuis JR, Barbarotto G. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect Chemother 2002; 8:201-6; PMID:12373481; https://doi.org/http://dx.doi.org/10.1007/s10156-002-0178-6
- Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; PMID:25855300
- Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53; PMID:25171469
- Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-50; PMID:21737702; https://doi.org/http://dx.doi.org/10.1126/science.1204839
- Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 2009; 83:6494-507; PMID:19386704; https://doi.org/http://dx.doi.org/10.1128/JVI.00286-09
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; https://doi.org/http://dx.doi.org/10.1038/nri2155
- Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 2013; 9:e1003312; PMID:23637602; https://doi.org/http://dx.doi.org/10.1371/journal.ppat.1003312
- Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, et al. Antibody treatment of ebola and sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep 2016; 15:1514-26; PMID:27160900; https://doi.org/http://dx.doi.org/10.1016/j.celrep.2016.04.026
- Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-8; PMID:24172905
- Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-80; PMID:24172896
- Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ. The maturation of antibody technology for the HIV epidemic. Immunol Cell Biol 2014; 92:570-7; PMID:24797582
- Lu D, Zhu Z. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion. Hum Monoclonal Antibodies: Springer 2014:185-213; PMID:24037843; https://doi.org/http://dx.doi.org/10.1007/978-1-62703-586-6_11
- Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci 2013; 110:13540-5; PMID:23878231; https://doi.org/http://dx.doi.org/10.1073/pnas.1304985110
- Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; https://doi.org/http://dx.doi.org/10.1159/000101046
- Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, et al. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci 2014; 111:16820-5; PMID:25385586; https://doi.org/http://dx.doi.org/10.1073/pnas.1408605111
- Zanin M, Keck Z-Y, Rainey GJ, Lam C-YK, Boon AC, Rubrum A, Darnell D, Wong SS, Griffin Y, Xia J, et al. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. J Virol 2015; 89:4549-61; PMID:25673719; https://doi.org/http://dx.doi.org/10.1128/JVI.00078-15
- Asokan M, Rudicell R, Louder M, McKee K, O'l S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. J Virol 2015; 89:12501-12; PMID:26446600; https://doi.org/http://dx.doi.org/10.1128/JVI.02097-15
- Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci 2012; 109:875-80; PMID:22219363; https://doi.org/http://dx.doi.org/10.1073/pnas.1120059109
- Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell 2016; 165:1609-20; PMID:27315478; https://doi.org/http://dx.doi.org/10.1016/j.cell.2016.04.050
- Tan W, Meng Y, Li H, Chen Y, Han S, Zeng J, Huang A, Li B, Zhang Y, Guo Y. A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. MAbs: Taylor & Francis 2013:946-55; PMID:24492346; https://doi.org/http://dx.doi.org/10.4161/mabs.26390
- Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, Li X, Zhao H, Xia T, Meng Y, et al. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. mAbs: Taylor & Francis 2016:574-84; PMID:26905804; https://doi.org/http://dx.doi.org/10.1080/19420862.2016.1148850
- Brien JD, Sukupolvi-Petty S, Williams KL, Lam C-YK, Schmid MA, Johnson S, Harris E, Diamond MS. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol 2013; 87:7747-53; PMID:23658441; https://doi.org/http://dx.doi.org/10.1128/JVI.00327-13
- Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR. Bispecific antibody affords complete post-exposure protection of mice from both Ebola (Zaire) and Sudan Viruses. Sci Rep 2016; 6:19193; PMID:26758505; https://doi.org/http://dx.doi.org/10.1038/srep19193
- Sun M, Pace CS, Yao X, Yu F, Padte NN, Huang Y, Seaman MS, Li Q, Ho DD. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J Acquired Immune Defic Syndr (1999) 2014; 66:473-83; PMID:24853313; https://doi.org/http://dx.doi.org/10.1097/QAI.0000000000000218
- Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 2016; 165:1621-31; PMID:27315479; https://doi.org/http://dx.doi.org/10.1016/j.cell.2016.05.024
- Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, et al. A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses. Science 2016; 354:350-354; PMID:27608667
- Taylor RP, Martin EN, Reinagel ML, Nardin A, Craig M, Choice Q, Schlimgen R, Greenbaum S, Incardona NL, Ochs HD. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 1997; 159:4035-44; PMID:9378993
- Taylor RP, Sutherland WM, Martin EN, Ferguson PJ, Reinagel ML, Gilbert E, Lopez K, Incardona NL, Ochs HD. Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol 1997; 158:842-50; PMID:8993002
- Hahn CS, French OG, Foley P, Martin EN, Taylor RP. Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a Monkey model of passive viremia. J Immunol 2001; 166:1057-65; PMID:11145685; https://doi.org/http://dx.doi.org/10.4049/jimmunol.166.2.1057
- Nardin A, Sutherland WM, Hevey M, Schmaljohn A, Taylor RP. Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes. J Immunol Methods 1998; 211:21-31; PMID:9617828; https://doi.org/http://dx.doi.org/10.1016/S0022-1759(97)00168-3
- Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Disc Today 2005; 10:1237-44; PMID:16213416; https://doi.org/http://dx.doi.org/10.1016/S1359-6446(05)03554-3
- Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE. Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody. Biol Blood Marrow Transplantation 2012; 18:1012-22; PMID:22313635; https://doi.org/http://dx.doi.org/10.1016/j.bbmt.2012.01.022
- Hua CK, Ackerman ME. Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Del Rev 2016; 103:157-73; PMID:26827912
- Shan L, Siliciano RF. From reactivation of latent HIV‐1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication. Bioessays 2013; 35:544-52; PMID:23613347; https://doi.org/http://dx.doi.org/10.1002/bies.201200170
- Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam C-YK, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, et al. Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells. J Clin Investigat 2015; 125:4077-90; PMID:26413868; https://doi.org/http://dx.doi.org/10.1172/JCI82314
- Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat Commun 2015; 6:8447; PMID:26485194
- Pant N, Marcotte H, Hermans P, Bezemer S, Frenken L, Johansen K, Hammarström L. Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Fut Microbiol 2011; 6:583-93; PMID:21585264; https://doi.org/http://dx.doi.org/10.2217/fmb.11.32
- Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PloS One 2011; 6:e17665; PMID:21483777; https://doi.org/http://dx.doi.org/10.1371/journal.pone.0017665
- Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci 2013; 110:5145-50; PMID:23479652; https://doi.org/http://dx.doi.org/10.1073/pnas.1220145110
- Strop P, Ho W-H, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; https://doi.org/http://dx.doi.org/10.1016/j.jmb.2012.04.020
- Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly JF, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs: Taylor & Francis 2013:646-54; PMID:23924797; https://doi.org/http://dx.doi.org/10.4161/mabs.25632
- Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; https://doi.org/http://dx.doi.org/10.1093/protein/gzq028